Equities

Kainos Laboratories Inc

4556:TYO

Kainos Laboratories Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,195.00
  • Today's Change-17.00 / -1.40%
  • Shares traded1.20k
  • 1 Year change+11.58%
  • Beta0.8009
Data delayed at least 20 minutes, as of Nov 15 2024 05:15 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments3,1743,0202,677
Total Receivables, Net1,5661,4111,333
Total Inventory879749648
Prepaid expenses9.96136.91
Other current assets, total652626
Total current assets5,6945,2194,690
Property, plant & equipment, net2,5062,5472,535
Goodwill, net------
Intangibles, net173157
Long term investments219168155
Note receivable - long term------
Other long term assets181819
Total assets8,5918,1167,572
LIABILITIES
Accounts payable529448536
Accrued expenses280292274
Notes payable/short-term debt240240280
Current portion long-term debt/capital leases324240132
Other current liabilities, total608696559
Total current liabilities1,9801,9161,781
Total long term debt307469544
Total debt871950956
Deferred income tax------
Minority interest------
Other liabilities, total376146
Total liabilities2,3252,4462,371
SHAREHOLDERS EQUITY
Common stock831831831
Additional paid-in capital940940940
Retained earnings (accumulated deficit)4,6504,1233,666
Treasury stock - common(247)(269)(269)
Unrealized gain (loss)924432
Other equity, total0.000.000.00
Total equity6,2665,6705,200
Total liabilities & shareholders' equity8,5918,1167,572
Total common shares outstanding4.224.174.17
Treasury shares - common primary issue0.340.380.39
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.